SITC Press Releases

Oncology News Burst from the FDA: FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 4 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

By SITC Communications posted 24 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Retifanlimab-dlwr With Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

By SITC Communications posted 05-16-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting

By Thomas Martin posted 05-13-2025
SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting Celebrating 40 years of driving breakthroughs in cancer immunotherapy MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Jennifer A. Wargo, MD, MMSc, from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 40 th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2025) with her presentation “Targeting the Microbiome to Promote Health and End Cancer.” SITC also hosts Ira Mellman, PhD, FAACR, ...
0 comments

Oncology News Burst from the FDA: FDA Approves Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

By SITC Communications posted 04-25-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

By SITC Communications posted 04-14-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

By SITC Communications posted 04-09-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab for Muscle Invasive Bladder Cancer

By SITC Communications posted 04-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Thanks FDA Leaders for Their Service

By Keegan Mager posted 03-31-2025
Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) would like to thank Peter Marks, MD, PhD, Marc Theoret, MD, and Paul Kluetz, MD, of the U.S. Food and Drug Administration (FDA) for their significant contributions across the field of oncology and their positive impact on public health. The development of cancer immunotherapy as we know it today - serving as first-line treatment for numerous cancer types - represents one such advance in oncology that would not have been possible without the tireless work ethic, collaboration, and determination of these individuals to improve ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

By SITC Communications posted 01-02-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

The Arthur and Sandra Irving Cancer Symposium: Connect with Senior Cancer Immunology Faculty and Learn from Their Experience in Research

By SITC Communications posted 12-17-2024
From June 22-25, 2025, the Arthur and Sandra Irving Cancer Immunology Symposium in Boston will connect promising young researchers with leaders in the field. Participants gain insights through interactive sessions and one -on-one mentoring to support the next stage of scientific and professional development. Young scientists face numerous challenges navigating the cancer immunology landscape. With the support of the Arthur and Sandra Irving Foundation, we aim to provide early-career researchers with the mentorship and tools they need to advance scientific discovery and make ...
0 comments

Oncology News Burst from the FDA: FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

By SITC Communications posted 12-16-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

By SITC Communications posted 12-06-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute lymphoblastic leukemia

By SITC Communications posted 11-11-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39th Annual Meeting

By Thomas Martin posted 11-01-2024
The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39 th Annual Meeting The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC’s upcoming 39 th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, ...
0 comments